Acute lung injury (ALI) is a serious inflammation disease usually arises alveolar epithelial membrane dysfunction and even causes death. Therefore, the aims of this study are to screen the differentially expressed lncRNAs, circRNAs, miRNAs, and mRNAs in ALI based on the high-throughput sequencing. The lipopolysaccharide (LPS)-induced ALI mouse model was established, the injury of ALI mouse model was evaluated through histological analysis with hemotoxylin and eosin (H & E) staining assay, dry/wet ratio, infiltrated-immune cells, ET-1 mRNA expression and released-proinflammation factors. Then, expression data of lncRNAs, circRNAs, miRNAs and mRNAs in ALI were acquired using whole-transcriptome sequencing. The differential expression of lncRNAs (DE lncRNAs), circRNAs (DE circRNAs), miRNAs (DE miRNAs) and mRNAs (DE mRNAs) were identified, and the lncRNA-miRNA-mRNA network and circRNA-miRNA-mRNA network were constructed, and the biological function of target genes were annotated based on bioinformatics analysis. In the present study, the LPS-induced ALI mouse model was successfully established. The biological analysis results showed that total 201 DE lncRNAs, 172 DE circRNAs, 62 DE miRNAs, and 3081 DE mRNAs were identified in ALI. The 182 lncRNA-miRNA-mRNA networks and 32 circRNA-miRNA-mRNA networks were constructed were constructed based on the correlation between lncRNAs/circRNAs, miRNAs, mRNAs. The biological function analysis indicated that TNF signaling pathway, chemokine signaling pathway and so on involved in ALI. In the present study, the differential expression coding and non-coding RNAs (ncRNAs) in ALI were identified, and their regulatory networks were constructed. There might provide the potential biomarkers and underlying mechanism for ALI diagnosis and treatment.

Development of thoracoscopic surgical skills and concepts in minimally invasive esophagectomy (MIE) and robotic-assisted (MIE) have provided us with a more wider anatomical understanding of lymphadenectomy and the relationship between lymph node dissection and recurrent laryngeal nerve paralysis (RLNP). However, RLNP correlates to postoperative complications even in prognosis. Early warning and novel diagnosis are urgent in the management of esophageal cancer patients. Taking a novel approach to researching the diagnosis of RLNP, we evaluated movement of the vocal cords and arytenoid cartilages using ultrasonography in patients who underwent thoracoscopic esophagectomy after extubating of trachea cannula at department of critical care medicine. Further ultrasonography combined endoscopy evaluation and verification were performed on day 5–7 before hospital discharge. RLNP occurred in 4 of the 20 patients’ cohort (20%). All of 20 patients were finished ultrasonography combined endoscopy evaluation. The diagnostic accuracy of RLNP by ultrasonography compared to endoscopy had a sensitivity of 100.0% (4/4), a specificity of 87.5% (14/16). The positive predictive value was 66.7% (4/6), negative predictive value was 100.0% (14/14), a false positive rate of 33.3% (2/6), and a false negative rate of 0% (0/14). Ultrasonography is a quite non-invasive and effective measure to diagnose and evaluate RLNP after esophagectomy compared to traditional examination of endoscopy. It also has a perspective future in evaluation for the recovery status of RLNP.

BackgroundOver the past decade, ECMO has provided temporary cardiopulmonary support to an increasing number of patients, but the use of extracorporeal membrane oxygenation (ECMO) to provide temporary respiratory and circulatory support to adult patients with malignancy remains controversial.ObjectivesThis paper reviews the specific use of extracorporeal membrane oxygenation (ECMO) in oncology patients.MethodsWe searched PubMed, CINAHL, Cochrane Library, and Embase databases for studies on the use of ECMO in cancer patients between 1998 and 2022. Twenty‐four retrospective, prospective, and case reports were included. The primary outcome was survival during extracorporeal membrane oxygenation.ResultsMost studies suggest that ECMO can be used in oncology patients requiring life support during surgery, solid tumor patients with respiratory failure, and hematological tumor patients requiring ECOM as a supportive means of chemotherapy; however, in patients with hematologic oncology undergoing hematopoietic stem cell transplantation, there was no clear benefit after the use of ECMO.ConclusionCurrent research suggests that ECMO may be considered as a salvage support in specific cancer patients. Future studies should include larger sample sizes than those already conducted, including studies on efficacy, adverse events, and health.